Mizuho Reiterates Neutral on Neurocrine Biosciences, Maintains $113 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has reiterated a Neutral rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $113.
September 13, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mizuho analyst has reiterated a Neutral rating on Neurocrine Biosciences and maintained a price target of $113.
The news is directly about Neurocrine Biosciences. Mizuho's reiteration of a Neutral rating and maintenance of the price target suggests that they do not expect significant changes in the stock's performance in the short term. This is likely to have a neutral impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100